StageAcquired | Acquired
Agensys develops therapeutic human monoclonal antibodies and antibody-drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, kidney, bladder, lung, and colon cancers. The company was founded in 1997 and is based in Santa Monica, California.
Missing: Agensys's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Agensys's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Agensys
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Agensys is included in 1 Expert Collection, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Agensys has filed 161 patents.
The 3 most popular patent topics include:
- Monoclonal antibodies
- Experimental cancer drugs
- Monoclonal antibodies for tumors
Monoclonal antibodies, Experimental cancer drugs, Monoclonal antibodies for tumors, Immunology, Clusters of differentiation
Monoclonal antibodies, Experimental cancer drugs, Monoclonal antibodies for tumors, Immunology, Clusters of differentiation
Latest Agensys News
Apr 24, 2023
" - https://www.reportlinker.com/p06451206/?utm_source=GNW , Sesen Bio Inc., Gilead Sciences Inc., Seagen Inc., Eisai Co Ltd., Agensys Inc. The global urothelial cancer drugs market is expected to grow from $1.91 billion in 2023 to $2.33 billion in 2023 at a compound annual growth rate (CAGR) of 21.98%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The urothelial cancer drugs market is expected to reach $4.80 billion in 2027 at a CAGR of 19.81%. The urothelial cancer drugs market consist of sales of targeted therapy urothelial cancer drugs and chemo therapy urothelial cancer drugs.Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. Urothelial cancer drugs refer to medicines and therapies that treat cancer associated with urothelial cells that line the urethra, bladder, ureters, and renal pelvis.These are used to kill tumour cells and provide non-vesical chemotherapy. The urothelial cancer drug is used to prevent and treat urothelial cancer. North America was the largest region in the urothelial cancer drugs market in 2022.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urothelial cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The main types of urothelial cancer drugs are urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma.The urothelial carcinoma is used to treat epithelial tissue tumors. Urothelial carcinoma refers to transitional cell cancer that occurs near epithelial tissues.The urothelial cancer drugs are used to treat immunotherapy, chemotherapy, and preservation therapy. The urothelial cancer drugs are distributed by hospital pharmacies, specialty clinics, cancer institutes, and ambulatory surgical centers. The rising prevalence of urothelial cancer is expected to propel the urothelial cancer drug market going forward.Urothelial cancer is associated with urothelial cells that line the urethra, bladder, ureters, renal pelvis, and some other organs. The rising prevalence of urothelial cancer requires novel urothelial cancer drugs and therapies for treatment to reduce fatalities.For instance, in February 2022, according to the American Society of Clinical Oncology, a US-based professional organization, the total number of people diagnosed with bladder cancer was 573,278 and 212,536 people died from bladder cancer in 2020 across the globe. Thus, the rising prevalence of urothelial cancer will drive the urothelial cancer drug market. Novel combination therapies are the key trends gaining popularity in the urothelial cancer drug market.Combination therapy combines two or more therapeutic agents for the treatment. Major players are concentrating on creating combination therapies to sustain their position in the urothelial cancer drug market.Combining immunotherapy with targeted drugs is an appealing treatment to reduce the emergence of resistance and improve response in cancer management. For instance, in July 2022, the United States Food and Drug Administration, a US-based federal agency of the Department of Health and Human Services, accepted the biologics license application (BLA) for an IL-15 superagonist, ImmunityBio’s N-803 in combination with Bacillus Calmette-Guerin (BCG) vaccine for bladder cancer. N-803 in combination with BCG would be the first immunotherapy combination that can be delivered directly to induce natural killer cells and T cells in the bladder. Rising prevalence of the geriatric population is driving the urothelial cancer drugs market.Adults 65 and older are referred to as members of the geriatric population. Due to lowered immunity and advanced age, the elderly population is susceptible to many diseases.The risk of urothelial cancer rises with age, due to which urothelial cancer drugs are required to treat them. For instance, according to the September 2020 report of the UN Department of Economic and Social Affairs, the population over the age of 65 is expected to increase from 9.3% in 2020 to almost 16.0% in 2050. Therefore, the rising prevalence of the geriatric population will propel the urothelial cancer drug market. The countries covered in the Urothelial Cancer Drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The urothelial cancer drugs market research report is one of a series of new reports that provides urothelial cancer drugs market statistics, including urothelial cancer drugs industry global market size, regional shares, competitors with a urothelial cancer drugs market share, detailed urothelial cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the urothelial cancer drugs industry. This urothelial cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Agensys Frequently Asked Questions (FAQ)
When was Agensys founded?
Agensys was founded in 1997.
Where is Agensys's headquarters?
Agensys's headquarters is located at 1545 17th Street, Santa Monica.
What is Agensys's latest funding round?
Agensys's latest funding round is Acquired.
How much did Agensys raise?
Agensys raised a total of $103.4M.
Who are the investors of Agensys?
Investors of Agensys include Astellas Pharma, LODH Private Equity Partners, Tekla Capital Management, HBM Partners, Bear Stearns and 13 more.
Who are Agensys's competitors?
Competitors of Agensys include Lipella Pharmaceuticals, Abeome, Array Biopharma, Alethia BioTherapeutics, Biosceptre International, Pique Therapeutics, ARIAD Pharmaceuticals, Dendreon, Open Monoclonal Technology, Human Genome Sciences and 14 more.
Compare Agensys to Competitors
Aliva Biopharmaceuticals is a company that received a SBIR Phase I grant for a project entitled: Humanized Mouse Ig system employing BAC. Their research project aims to introduce the entire human immunoglobulin locus into the mouse in order to enable the subsequent production of completely humanized monoclonal antibodies from hybridomas. Monoclonal antibodies against cell surface proteins are currently being used for a variety of clinical indications, including cancer and autoimmunity. Their binding avidity and specificity make them one of the most important modes of therapy for the treatment of a variety of diseases where specific targeting is required. The current technology is based on a system where only 80% of the immunoglobulin locus has been humanized. Replacement of the remaining mouse genes with the human ones will improve the quality and diversity of the antibodies produced and as such, will be an important contribution to this important therapeutic modality.
Spaltudaq Corporation, a privately-held biotechnology company based in Seattle, is focused on developing therapeutic antibodies for the treatment of inflammation, infectious disease and cancer. Our technology harnesses the power of the human immune system to identify tumor-specific or pathogen-specific monoclonal antibodies from human tissue samples.
Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.
Biosceptre has identified a pan-cancer target, present in many cancer types, and importantly not found in healthy tissue. Early research and initial evidence suggest that drugs directed at the nf-P2X7 target have the potential to redefine cancer therapy. The Company has raised AUD33m and will be raising further capital through both existing and new investors. Biosceptre has a rigorous, international patent portfolio extending to 2032, providing broad protection of the target and specific protection of antibody products. The Company is developing therapeutics and diagnostics to bind nf-P2X7, with the core of product development in topical and systemic cancer drugs. Biosceptreis also developing an immuno-oncology vaccine, through an existing collaboration, and is in discussions with developmental partners to develop diagnostic and imaging technologies to detect and monitor cancer. Biosceptre is supported by a world-class scientific advisory board, the members of which have been central in the development of numerous, highly successful, biotechnology companies and products. The Company has the team, capital, and plan to create substantial value from this unique, patent-protected, technology. The business is headquartered in Cambridge, UK with additional research facilities in Sydney, Australia.
Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.
Abraxis BioScience is a biotechnology company dedicated to delivering progressive therapeutics and core technologies that offer patients and medical professionals safer and more effective treatments for cancer and other critical illnesses. The Abraxis portfolio includes the protein-based nanoparticle chemotherapeutic compound (ABRAXANE) which is based on its tumor targeting system known as the nab' Technology platform.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.